ethyl 2-(3,4-diaminophenoxy)acetate | 742073-16-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: ethyl 2-(3,4-diaminophenoxy)acetate
• CAS: 742073-16-1
• 化学式: C₁₀H₁₄N₂O₃
• mdl: MFCD24390473
• 分子量: 210.233
• InChiKey: AEYWVMNYOSSIJE-UHFFFAOYSA-N

物化性质

• 沸点：
  378.5±27.0 °C(Predicted)
• 密度：
  1.229±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  15
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  87.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  ethyl 2-(3,4-diaminophenoxy)acetate 在 sodium hydroxide 、 O-(benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborate 、 sodium hydrogensulfite 作用下， 以 N-甲基吡咯烷酮 、 甲醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.0h， 生成 2-[2-(5-Chloro-thiophen-2-yl)-1H-benzoimidazol-5-yloxy]-N-[3-methyl-4-(3-oxo-morpholin-4-yl)-phenyl]-acetamide
  参考文献：
  名称：

  Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa

  摘要：

  Neutral weak halothiophene benzimidazole inhibitors of the serine protease factor Xa were identified via screening of a compound library. The X-ray crystal structure of representative 3a bound to human fXa confirmed the S1 binding mode. Starting from 3a a series of halothiophene benzimidazoles was synthesized and investigated for their factor Xa inhibitory activity. This led to potent and selective achiral inhibitors against fXa such as compounds 9k and 9w. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.097
• 作为产物：
  描述：

  ethyl 2-(3,4-dinitrophenoxy)acetate 在 镍 氢气 作用下， 以 四氢呋喃 为溶剂， 反应 4.0h， 生成 ethyl 2-(3,4-diaminophenoxy)acetate
  参考文献：
  名称：

  Halothiophene benzimidazoles as P1 surrogates of inhibitors of blood coagulation factor Xa

  摘要：

  Neutral weak halothiophene benzimidazole inhibitors of the serine protease factor Xa were identified via screening of a compound library. The X-ray crystal structure of representative 3a bound to human fXa confirmed the S1 binding mode. Starting from 3a a series of halothiophene benzimidazoles was synthesized and investigated for their factor Xa inhibitory activity. This led to potent and selective achiral inhibitors against fXa such as compounds 9k and 9w. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.04.097

文献信息

• Easy conjugations between molecules via copper-catalyzed reactions of ortho-aromatic diamines with ketones
  作者：Juyou Lu、Haijun Yang、Yunhe Jin、Yuyang Jiang、Hua Fu

  DOI：10.1039/c3gc41585f

  日期：——

  It is a great challenge to achieve a useful reaction under benign conditions. In this paper, a highly efficient method for copper-catalyzed conjugations of o-aromatic diamines with ketones has been developed using benign chemistry. Interestingly, the conjugation between the biological small molecules worked very well.

  在温和条件下实现有用反应是一项巨大挑战。本文中，利用温和化学原理，开发出一种高效的方法，用于铜催化邻芳香二胺与酮的偶联反应。有趣的是，这种生物小分子间的偶联反应效果非常好。
• [EN] SELECTIVE NR2B ANTAGONISTS<br/>[FR] ANTAGONISTES SÉLECTIFS DU NR2B
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2013049119A1

  公开（公告）日：2013-04-04

  The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及到式(I)的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是配体，NR2B受体的拮抗剂，可能对治疗中枢神经系统的各种疾病有用。
• JAK-2 Modulators and Methods of Use
  申请人：Galan Adam Antoni

  公开号：US20100136136A1

  公开（公告）日：2010-06-03

  This invention relates to the field of protein tyrosine kinases and inhibitors thereof. In particular, the invention relates to inhibitors of JAK-2, pharmaceutical compositions of the compounds for inhibiting JAK-2, methods of inhibiting JAK-2 in a cell, comprising contacting a cell in which inhibition of JAK-2 is desired with a compound or pharmaceutical composition comprising a compound according to the invention. The also comprises methods of treating a disease or condition that involves JAK-2 comprising administering to a patient a pharmaceutical composition comprising a compound according to the invention.

  本发明涉及蛋白酪氨酸激酶及其抑制剂领域。具体而言，本发明涉及JAK-2的抑制剂，以及用于抑制JAK-2的化合物的制药组合物，包括通过将含有本发明化合物的化合物或制药组合物与需要抑制JAK-2的细胞接触来抑制JAK-2的细胞方法。本发明还包括治疗涉及JAK-2的疾病或病状的方法，包括向患者施用包含本发明化合物的制药组合物。
• Selective NR2B Antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US20130085138A1

  公开（公告）日：2013-04-04

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  本披露通常涉及公式I的化合物，包括它们的盐，以及使用这些化合物的组合物和方法。这些化合物是配体，是NR2B受体的拮抗剂，可能有助于治疗中枢神经系统的各种疾病。
• Selective NR2B antagonists
  申请人：Bristol-Myers Squibb Company

  公开号：US08722670B2

  公开（公告）日：2014-05-13

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands, antagonists of the NR2B receptor and may be useful for the treatment of various disorders of the central nervous system.

  该披露通常涉及I式化合物，包括其盐，以及使用该化合物的组合物和方法。这些化合物是配体，NR2B受体的拮抗剂，可能对治疗中枢神经系统的各种疾病有用。